StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Beat-and-raise earnings typically trigger multiple expansion and higher targets; yet immediate pre-market move was modest, suggesting cautious near-term participation but clear positive trajectory over the next few quarters.
What happened, with direct paths to the underlying reporting
AbbVie delivered a strong Q3 with sales of $17.404 billion and adjusted EPS of $3.82, topping expectations. The company raised 2026 guidance to $67.8 billion in revenue and $13.95-$13.99 in adjusted EPS, signaling sustained momentum across its portfolio. Pre-market trading moved modestly higher as analysts bumped target prices to $325–$338, underscoring a constructive sentiment shift for ABBV near term.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.